Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    51,109.89
    -570.05 (-1.10%)
     

  • CMC Crypto 200

    1,327.58
    -68.95 (-4.94%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

J&J, Glaxo settle U.S. lawsuit over allergy ads

Reuters - UK Focus

(Updates with Glaxo comment in 3rd paragraph)

By Nate Raymond

NEW YORK, March 30 (Reuters) - GlaxoSmithKline Plc (Other OTC: GLAXF - news) has agreed to settle a lawsuit by Johnson & Johnson (NYSE: JNJ - news) accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

The settlement was disclosed during a hearing in Manhattan federal court on Monday in which two Johnson & Johnson units were expected to ask a judge to block Glaxo from making various claims about its allergy nasal spray Flonase, records show.

Representatives for Johnson & Johnson and Glaxo in separate statements called the settlement "mutually acceptable and amicable." The terms were confidential, they said.

ADVERTISEMENT

Glaxo received approval from the U.S. Food and Drug Administration to sell Flonase over the counter in July, setting the stage for greater competition.

J&J units McNeil-PPC Inc and McNeil Consumer Healthcare filed the lawsuit on March 12, accusing Glaxo of making unsupported claims about Flonase at the expense of McNeil's drugs Benadryl and Zyrtec.

A Glaxo TV spot cited in the lawsuit said that Flonase outperforms the No. 1 allergy pill, which the ad does not name, and controls six allergy symptoms versus one by the other pill.

The McNeil units said studies do not support the claims. McNeil said it stood to be harmed with the prime allergy sales season quickly approaching, and sought an injunction.

The case is McNeil-PPC Inc and McNeil Consumer Healthcare v. GlaxoSmithKline Consumer Healthcare LP, U.S. District Court for the Southern District of New York, No. 15-1866. (Reporting by Nate Raymond in New York; Editing by Ted Botha)